Antares Pharma, Inc.

Gel reduces hot flashes in menopausal women

Published in Women's Health Law Weekly, August 14th, 2005

Antares Pharma, Inc., (AIS) announced that its North American licensee, BioSante Pharmaceuticals, Inc., has announced significant phase III safety and efficacy results of bioidentical estradiol transdermal gel (Bio-E-Gel) for the treatment of moderate-to-severe hot flashes in menopausal women.

A new drug application (NDA) is expected to be filed as soon as possible after completion of the data analysis, which is projected to be around the end of September.

Bio-E-Gel utilizes Antares Pharma's proprietary Advanced Transdermal Delivery (ATD) gel system, which is designed to allow delivery of hormones and other active ingredients across the skin. Antares...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Women's Health Law Weekly

Source: Women's Health Law Weekly (2005-08-14)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry